Sanara MedTech Inc.
SMTIHealthcareNASDAQMedical Instruments & Supplies · Last scanned Oct 26, 2026
Scan Results
Daily timeframeSanara MedTech Inc., a medical technology company, develops, markets, and distributes surgical solutions to physicians, hospitals, clinics, and post-acute care settings in the United States. Valued at $301.4M, SMTI is a small-cap name in its sector. The company offers CellerateRX Surgical, a medical hydrolysate of Type I bovine collagen indicated for the management of surgical, traumatic, and partial- and full-thickness wounds, as well as first- and second-degree burns.
Market Cap
$301.4M
Beta
1.19
P/E (TTM)
—
P/E (Fwd)
60.74
EPS (TTM)
$-0.04
EPS (Fwd)
$0.54
ROE
-1.3%
ROA
7.6%
Cash
$15.4M
Total Debt
$48.5M
Free CF
$5.7M
52W Change
7.5%
Annual Financials
Cash vs Debt
Where SMTI stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, SMTI finished 25.58% above its 150-day moving average ($26.39) and 32.14% above its 200-day moving average ($25.08). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is SMTI overbought or oversold?
At the October 20, 2026 close, SMTI's RSI(14) was 13.2, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The company holds $15.4M in cash, though total debt stands at $48.5M. This level of leverage is common in the industry but worth monitoring as interest rate conditions evolve. Annual free cash flow of $5.7M supports ongoing capital allocation decisions and provides a cushion against unexpected expenses or downturns. ROE of -1.3% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. An ROA of 7.6% suggests reasonable efficiency in deploying the company's asset base. Revenue has grown from $45.8M (2022) to $103.1M (2025), reflecting a 125% increase over the period.
Investors considering Sanara MedTech Inc. should weigh the typical risks associated with SMTI's sector, size, and financial profile against their own risk tolerance and investment objectives. No single metric tells the full story. Reviewing SMTI's risk profile alongside its fundamentals and technical indicators provides a more complete picture.